New knee osteoarthritis treatment shows promise in early human test
NCT ID NCT06539429
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a new biological treatment called ANT-301 in 6 people with severe knee osteoarthritis. The main goal is to check safety, but researchers will also measure pain and knee function. If safe, larger studies could follow to see if it truly helps.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ANT-301 (a biological product made from cells)
- What this could lead to
- If it works, this could point toward a new treatment to control knee osteoarthritis pain and improve function.
- What could go wrong
- This is a very early, tiny trial with only 6 people. It mainly checks safety, not effectiveness. The treatment may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 6 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients who have been provided with information about the clinical trial and have provided written consent on the informed consent form 2. Patients aged 19 to 70 years old. 3. Patients diagnosed with K\&L grade III/IV knee osteoarthritis 4. Patients with a VAS pain score of 40mm or higher when measured on a 100-point scale Exclusion Criteria: 1. Patients with joint diseases other than osteoarthritis 2. Patients who have undergone knee joint surgery or radiation therapy to the knee joint within 6 months prior to the screening 3. Patients who received intra-articular injections within 6 months prior to the screening 4. Patients who have received systemic steroid therapy within 3 months prior to the screening 5. Patients who have received immunosuppressive agents within 3 months prior to the screening 6. Patients who have received cell therapy or gene therapy to the target knee within 5 years prior to the screening 7. Patients who are unwilling to use contraception during the clinical trial period
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Osteoarthritis, knee are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University
Seoul, Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which anesthesia gets joint replacement patients moving sooner?
- Can a special MRI match CT for spotting knee bone damage?
- Can a common bleeding drug make knee realignment surgery safer?
- One shot, new knee? gene therapy trial aims to quiet arthritis pain
- Three knee shots go Head-to-Head for lasting arthritis relief
- Gel shot vs standard injection: which quiets arthritic knees?